Skip to main content
Journal ArticleOPEN ACCESS

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

  • Morabito A
  • Piccirillo M
  • Falasconi F
  • et al.
The Oncologist (2009) 14(4) 378-390
DOI: 10.1634/theoncologist.2008-0261
193Citations
Citations of this article
157Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Evaluate the mechanism of action of vandetanib in the care of patients with thyroid cancer. Analyze the current status of clinical development and early clinical results observed with vandetanib. Determine appropriate dose and schedule of administration, safety, and identification of molecular biomarkers predictive of response.This article is available for continuing medical education credit at CME.TheOncologist.com.

Cite

CITATION STYLE

APA

Morabito, A., Piccirillo, M. C., Falasconi, F., De Feo, G., Del Giudice, A., Bryce, J., … Perrone, F. (2009). Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. The Oncologist, 14(4), 378–390. https://doi.org/10.1634/theoncologist.2008-0261

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free